Optomed Oyj Class A · OMXHEX:OPTOMED
Optomed Oyj Class A — Redeye Growth Day 2020
12 slides from Optomed Oyj Class A's conference presentation, Jun 2, 2020
Slide 1: Redeye Growth Day 2020 – Optomed
June 2nd 2020, Seppo Kopsala, CEO / Lars Lindqvist, CFO
Slide 2: Handheld fundus cameras and AI software for screening blinding eye diseases
6 We fer our customers leading handheld fundus cameras and software solutions with integrated Artificial Intelligence (Al) for P screening of blinding eye diseases
Slide 3: Total number of adults with diabetes (20-79 years), millions
Total number of adults with diabetes (20-79 years), millions(1) 629 Western Pacific 41 South East Asia 42 425 82 Europe 16 62 26 North America & Caribbean 39 67 46 Middle East and North Africa 58 151 108 82 South and Central America 159 183 Africa 1980(2) 2017 2045E 1) Source: International Diabetes
Slide 4: ~1/3 of diabetics expected to be affected by DR; everyone needs screening
~1/3 of diabetics are expected to be affected by DR. However, everyone is in need of screening . 114.4m diabetics 72.9m diabetics 30.2m diabetics 12.5m diabetics 58m diabetics(3) *screening *screening *screening *screening *screening coverage <5% coverage <50% coverage <35% coverage between coverage
Slide 5: Traditional stationary equipment and eye doctors reach a small fraction of diabetics
Traditional stationary equipment and eye doctors can only reach a small fraction of all diabetics sas . Optomed’s handheld : Traditional equipment .. together with Al 3o Low screening coverage Possibility to increase Possibility for increased Capacity constraints Screening coverage Volume capabiliti
Slide 6: Established 2004 in Finland to bring eye examinations to primary care
Established 2004 Listed on Nasdaq Offices: Finland; Oulu, 2 complementary Global pioneer and in Finland with the Helsinki main list in Espoo, Tampere; China; business segments: market leader in hand- aim of bringing eye December 2019. Shanghai, USA; San Devices and Software held fundus cameras. exam
Slide 7: Optomed products and solutions
Optomed products and solutions _ Jeb ~ | l | & Solutions 7 on y | + Al OPT@MED
Slide 8: Launching in 2020
Zee *Launching in 2020
Slide 9: Expansion to other diseases and preventive health-check in primary care
Eye-diseases Expansion to other diseases Preventive health-check in primary care Diabetic Retinopathy, age-related macular All eye disorders, neurological disorders, Eye disease, neurological disorders, degeneration (AMD), glaucoma kidney disease, cardiovascular risk Alzheimer’s disease, cardiovascu
Slide 10: Grow in existing markets and enter new markets; expanding distribution network
1. 2. 3 • Grow in existing markets and enter • Expansion into new customer • Bringing new products and solutions new markets segments to the market • Expanding distribution network • Primary care • New cameras • New AI capabilities
Slide 11: Revenue growth and adjusted EBITDA targets
Revenue Growth Adjusted EBITDA Optomed’s medium-term target is to deliver Optomed’s target is to prioritise a double-digit annual organic revenue investments in the organisation to growth. In the long-term Optomed’s target support growth in the medium-term and is to deliver an average annual organic
Slide 12: Optomed's mission is to prevent blindness by improving access to eye screening globally
74 Optomed's mission is to prevent blindness by improving access to eye screening globally OPT@MED